Geode Capital Management’s Allena Pharmaceuticals ALNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-386,352
| Closed | -$73K | – | 5066 |
|
|
2022
Q2 | $73K | Buy |
386,352
+50,779
| +15% | +$7.87K | ﹤0.01% | 4687 |
|
|
2022
Q1 | $77K | Buy |
335,573
+4,974
| +2% | +$2.06K | ﹤0.01% | 4724 |
|
|
2021
Q4 | $195K | Hold |
330,599
| – | – | ﹤0.01% | 4486 |
|
|
2021
Q3 | $298K | Buy |
330,599
+45,032
| +16% | +$44.1K | ﹤0.01% | 4274 |
|
|
2021
Q2 | $371K | Buy |
285,567
+29,323
| +11% | +$35.5K | ﹤0.01% | 4079 |
|
|
2021
Q1 | $356K | Buy |
256,244
+164,371
| +179% | +$274K | ﹤0.01% | 3926 |
|
|
2020
Q4 | $117K | Buy |
91,873
+20,924
| +29% | +$29.2K | ﹤0.01% | 4025 |
|
|
2020
Q3 | $105K | Sell |
70,949
-53,957
| -43% | -$75.8K | ﹤0.01% | 3893 |
|
|
2020
Q2 | $197K | Buy |
124,906
+16,584
| +15% | +$27.9K | ﹤0.01% | 3669 |
|
|
2020
Q1 | $104K | Buy |
108,322
+2,468
| +2% | +$4.94K | ﹤0.01% | 3752 |
|
|
2019
Q4 | $288K | Buy |
105,854
+53,719
| +103% | +$176K | ﹤0.01% | 3690 |
|
|
2019
Q3 | $205K | Buy |
52,135
+10,173
| +24% | +$43.7K | ﹤0.01% | 3756 |
|
|
2019
Q2 | $170K | Sell |
41,962
-35,283
| -46% | -$193K | ﹤0.01% | 3830 |
|
|
2019
Q1 | $542K | Buy |
77,245
+4,931
| +7% | +$35.8K | ﹤0.01% | 3409 |
|
|
2018
Q4 | $394K | Buy |
72,314
+5,444
| +8% | +$46.9K | ﹤0.01% | 3458 |
|
|
2018
Q3 | $718K | Buy |
66,870
+6,688
| +11% | +$73.5K | ﹤0.01% | 3340 |
|
|
2018
Q2 | $784K | Buy |
60,182
+49,133
| +445% | +$709K | ﹤0.01% | 3279 |
|
|
2018
Q1 | $121K | Buy |
+11,049
| New | +$92.3K | ﹤0.01% | 3802 |
|
Other funds holding ALNA
Geode Capital Management's ALNA Position: Q3 2022 in Review
Geode Capital Management sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 386,352 shares — an estimated $73K sold.
Geode Capital Management first reported a position in ALNA in Q1 2018 and held it in 18 quarters. The position peaked at $784K in Q2 2018. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.
- Geode Capital Management reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Geode Capital Management sold 386,352 Allena Pharmaceuticals shares in Q3 2022, an estimated $73K.
- Geode Capital Management first reported a position in Allena Pharmaceuticals in Q1 2018 and held it in 18 quarters.
- Geode Capital Management's Allena Pharmaceuticals position peaked at $784K in Q2 2018.
- 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.
Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.